医学
免疫疗法
结直肠癌
放射治疗
化疗
癌症
靶向治疗
抗药性
纳米医学
肿瘤科
内科学
生物
微生物学
纳米颗粒
纳米技术
材料科学
作者
Qingqing Pan,Fan Xi,Li Xie,Di Wu,Rong Liu,Wenxia Gao,Kui Luo,Bin He,Yuji Pu
标识
DOI:10.1016/j.jconrel.2023.09.014
摘要
Colorectal cancer (CRC), one of the most common and deadliest diseases worldwide, poses a great health threat and social burden. The clinical treatments of CRC encompassing surgery, chemotherapy, and radiotherapy are challenged with toxicity, therapy resistance, and recurrence. In the past two decades, targeted therapy and immunotherapy have greatly improved the therapeutic benefits of CRC patients but they still suffer from drug resistance and low response rates. Very recently, gut microbiota regulation has exhibited a great potential in preventing and treating CRC, as well as in modulating the efficacy and toxicity of chemotherapy and immunotherapy. In this review, we provide a cutting-edge summary of nanomedicine-based treatment in colorectal cancer, highlighting the recent progress of oral and systemic tumor-targeting and/or tumor-activatable drug delivery systems as well as novel therapeutic strategies against CRC, including nano-sensitizing immunotherapy, anti-inflammation, gut microbiota modulation therapy, etc. Finally, the recent endeavors to address therapy resistance, metastasis, and recurrence in CRC were discussed. We hope this review could offer insight into the design and development of nanomedicines for CRC and beyond.
科研通智能强力驱动
Strongly Powered by AbleSci AI